文献速递头颈与中枢神经肿瘤

瑞戈非尼治疗新诊断与复发胶质母细胞瘤:GBM AGILE II/III期贝叶斯随机平台试验

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
PubMed 文献 · J Clin Oncol · 2026-04-14

GBM AGILE是一项II/III期贝叶斯自适应平台注册试验,以总生存期(OS)为主要终点,将瑞戈非尼与共同对照比较。瑞戈非尼组纳入新诊断未甲基化(NDU)和复发(RD)胶质母细胞瘤,最终分析未显示OS改善,中位HR分别为1.05(NDU)、1.07(RD)和1.07(全部),且毒性增加。

要点

  • 瑞戈非尼在复发和新诊断未甲基化胶质母细胞瘤中均未显示OS获益。
  • 中位HR:NDU 1.05、RD 1.07、全部1.07,获益概率均低于98%阈值。
  • 瑞戈非尼相关毒性增加,已从NCCN复发胶质母细胞瘤治疗选项中移除。

核心结论

  • GBM AGILE未显示瑞戈非尼在复发(洛莫司汀对照)或新诊断未甲基化(替莫唑胺+放疗对照)胶质母细胞瘤中优于对照,且毒性增加。

研究设计与样本

  • GBM AGILE(NCT03970447)为II/III期贝叶斯自适应平台注册试验,测试多个臂与共同对照,主要终点为OS。
  • 瑞戈非尼臂纳入新诊断未甲基化(NDU)和复发(RD)胶质母细胞瘤患者,预设臂特征为NDU、RD和全部(NDU+RD)。
  • 瑞戈非尼作为首个研究臂与对照臂等比例随机分配;对照臂在新诊断中为替莫唑胺+放疗,在RD中为洛莫司汀。

主要发现

  • 当所有预设特征中瑞戈非尼的贝叶斯预测功效<25%时,因疗效有限停止入组。
  • 最终分析未显示瑞戈非尼在RD或NDU胶质母细胞瘤中改善OS。
  • 中位HR为1.05(NDU)、1.07(RD)和1.07(全部),最终获益概率(HR<1.00)分别为0.421(NDU)、0.312(RD)和0.296(全部)。
  • 瑞戈非尼相对于对照与毒性增加相关。

关键数值与推荐

  • 疗效通过OS风险比(HR,臂/对照)评估,当贝叶斯获益概率(HR<1.00)≥98%时判定为有效。
  • 每月进行疗效有限分析,当所有特征中贝叶斯预测功效<25%时停止入组。
  • 入组停止后继续随访12个月。

临床怎么用

  • 瑞戈非尼不应用于复发或新诊断未甲基化胶质母细胞瘤的常规治疗。
  • 瑞戈非尼已从NCCN指南中移除作为复发胶质母细胞瘤的治疗选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: GBM AGILE (ClinicalTrials.gov identifier: NCT03970447) is a phase II/III Bayesian adaptive platform registration trial testing multiple arms against a common control; the primary end point is overall survival (OS). Regorafenib, a multikinase inhibitor, showed OS benefit in recurrent (RD) glioblastoma in the phase II REGOMA trial and entered GBM AGILE as the first investigational arm. METHODS: Patient subtypes included in the regorafenib arm of GBM AGILE were newly diagnosed unmethylated (NDU) and RD glioblastoma. Prospective defined sets of subtypes, or arm signatures, were NDU, RD, and all (NDU + RD). As the first investigational arm in GBM AGILE, regorafenib was equally randomized to the control arm. Treatment in the control arm is temozolomide + radiotherapy (in newly diagnosed) or lomustine (in RD). Efficacy was assessed by OS hazard ratio (HR), arm/control, and demonstrated when the Bayesian probability of benefit (HR <1.00) was ≥98%. Analysis was performed monthly for limited efficacy, which occurs when the Bayesian predictive power is <25% for all signatures, and determines stopping enrollment. Follow-up continued for 12 months after accrual stopped. RESULTS: When the predictive power was <25% in all predefined signatures for regorafenib, accrual stopped for limited efficacy. The final analysis did not demonstrate OS improvement in the regorafenib arm in RD nor NDU glioblastoma. Median HRs were 1.05 (NDU), 1.07 (RD), and 1.07 (all) with final probabilities of benefit (HR <1.00) of 0.421 (NDU), 0.312 (RD), and 0.296 (all). Regorafenib was associated with increased toxicity relative to control. CONCLUSION: GBM AGILE did not show superiority of regorafenib over control in RD (lomustine) or NDU (temozolomide + radiotherapy) glioblastoma, yet caused increased toxicities. Regorafenib has been removed from National Comprehensive Cancer Network guidelines as a treatment option for RD.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wen PY, Berry DA, Buxton MB, et al. Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial. J Clin Oncol. 2026. PMID: 41980234. doi:10.1200/JCO-25-01137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。